Data presented at ASCO show that swapping in the oral drug camizestrant for an older therapy helped sustain the benefit of ...

This is the web version of STAT’s special newsletter from the annual meeting of the American Society of Oncology. For more ...

Pfizer (PFE) and Arvinas (ARVN) aim to seek FDA approval for thier breast cancer therapy vepdegestrant in H2 2025. Read more ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...

Pfizer's BRAFTOVI combo cut death risk by 51% and more than doubled survival in BRAF-mutant colorectal cancer in a Phase 3 ...

The trial was meant to answer the biggest question in biotech: What happens when U.S. companies test promising new Chinese ...

Western drugmakers, investors increasingly aim to acquire Chinese compounds.